Last reviewed · How we verify
Torasemide tablets
At a glance
| Generic name | Torasemide tablets |
|---|---|
| Sponsor | Jemincare |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure (PHASE4)
- Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (PHASE3)
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
- Bioavailability and Bioequivalence Study of ER Torsemide and Spironolactone FDC Tablet in Healthy Subjects (PHASE3)
- A Study to Evaluate the Effect of Food or no Food on the Bioavailability of an Extended Release (ER) Torsemide and Spironolactone Fixed Dose Combination (FDC) Tablet in Healthy Adult Subjects (PHASE3)
- A Comparative Bioavailability Study of Two Torasemide 10 mg Tablets Formulations in Healthy Adult Participants Under Fasting Conditions: (PHASE1)
- A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis (NA)
- A Dose-finding Study of JMKX003142 in Treatment of Renal Edema (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Torasemide tablets CI brief — competitive landscape report
- Torasemide tablets updates RSS · CI watch RSS
- Jemincare portfolio CI